RealPennies.com: Turning Pennies into dollars: (Pink Sheets: OEDV); (Pink Sheets: AFAO); (OTC: PLUS); (Pink Sheets: MLSC); (Pink Sheets: TAROF).
Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559
For more info: http://oedv.realpennies.com
Osage Exploration and Development, Inc. (Pink Sheets: OEDV) (January 9, 2008) is pleased to have announced earlier today that the engagement of Energy Capital Solutions, LP (ECS) of Dallas, Texas as sole financial advisor to assist the Company in evaluating and structuring a strategic producing acquisition. "We are pleased to have access to the highly skilled M&A team at ECS," stated Kim Bradford, chairman and CEO. "The transactional experience and energy that ECS brings to the table surpasses that of any other firm in our segment of the market," stated Ran Furman, CFO of Osage, "we look forward to building upon this relationship."
Based in La Jolla, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogota, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia.
Energy Capital Solutions, LP (ECS) is a Dallas, Texas based investment banking firm focused on raising private capital and providing merger and acquisition advisory services to public and private companies involved in the energy sector. Since its inception in 2001, ECS has raised over $2.2 billion in 67 financing transactions including private equity and debt financings and has advised on merger and acquisition transactions with an aggregate transaction value of approximately $1.9 billion.
For more info: http://afao.realpennies.com
SmallCapVoice.com, Inc. announced earlier today that a new audio interview featuring, Jon Goldwater, CEO of AFA Music Group, Ltd. (Pink Sheets: AFAO), is now available at SmallCapVoice.com. Mr. Goldwater provides his personal insight into the Company's milestones for 2007 and provides an outlook for 2008. The interview can be heard here at http://smallcapvoice.com/afao/afao-1-7-08.php.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its client's financial news releases. SmallCapVoice.com also offers individual investors with all the tools they need to make informed decisions about the stocks they are interested in. Tools like our stock charts, stock alerts, and our investor fact sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets.
AFA "Artists for Artists" is a talent development and management agency. Since being founded in 2005, and based on its philosophy, AFA has attracted a roster of 10 "major-quality" recording artists. AFA Music Group plans on simultaneously acquiring various music-publishing assets and to begin developing its own catalogue of artists and albums.
For more info: http://otc.realpennies.com
ePlus inc. (OTC: PLUS)(January 9, 2008) announced earlier today that it has successfully completed an unqualified SAS 70 Type II examination for its eProcurement and Content Management solutions. The Type II report, which was issued by an independent CPA firm and is based on established accounting principles, demonstrates that control activities supporting the company's hosted applications are designed and operating effectively.
The SAS 70 Type II report provides an authoritative and independent assessment of a service provider's adherence to process controls in alignment with Sarbanes-Oxley requirements. The examination was performed in accordance with standards established by the American Institute of Certified Public Accountants and included those procedures considered necessary in the circumstances to obtain a reasonable basis for rendering an opinion.
The ePlus SAS 70 report, conducted by one of the nation's leading CPA firms specializing in SAS 70 services, found both the design and operating effectiveness of controls supporting ePlus' eProcurement and Content solutions provided "reasonable assurance" that the specified control objectives were achieved during the period from April 1 to October 19 of this year.
The scope of the ePlus Type II examination included Procure+, the company's eProcurement solution providing catalog, bidding, ordering, inventory and invoice matching management for the entire purchasing process, and Content+ and the Supplier Portal, which enables suppliers to upload and maintain their online catalogs.
We believe that ePlus customers may be able to use the ePlus Type II report to support their compliance with Sarbanes-Oxley regulations for those services outsourced to ePlus.
ePlus Systems inc., a wholly owned subsidiary of ePlus inc., develops and markets advanced software applications and services to meet the needs of spend management and product content management for customers across all industries. The combination of software and services gives customers the choices and tools to optimize their spend, including supplier enablement, catalog content management, eProcurement, spend analytics, document management, and asset management.
ePlus is a leading provider of technology solutions. ePlus enables organizations to optimize their IT infrastructure and supply chain processes by delivering world-class IT products from top manufacturers, professional services, flexible lease financing, proprietary software, and patented business methods. Founded in 1990, ePlus has more than 625 associates in 30+ locations serving more than 2,500 customers.
For more info: http://mlsc.realpennies.com
Medical Discoveries, Inc., dba Global Clean Energy Holdings (Pink Sheets: MLSC) or "MDI/Global" announced today that it has recently filed with the Securities and Exchange Commission its Form 10-KSB for the fiscal year ended December 31, 2006 and its Form 10-Q for each of the quarters ended March 31, 2007, June 30, 2007 and September 30, 2007. With these filings, the Company is now current with all of its Securities and Exchange Commission reports and is eligible to reapply to have its common stock listed for trading on the Over-the-Counter OTC Bulletin Board. Accordingly, the Company expects to have a market maker file Form 211 in compliance with SEC Rule 15c2-11 and NASD Rule 6740. Once the filing is accepted by the FINRA, the Company will be eligible to begin trading on the Over-the-Counter Bulletin Board.
"We are excited by the progress the Company has made in the relatively short time since it commenced its new biofuels business and acquired Global Clean Energy Holdings, LLC," said Richard Palmer, MDI's President and newly appointed Chief Executive Officer. "We believe that becoming a fully-reporting company will create greater transparency for investors. In addition, we feel a listing on the Over-The-Counter Bulletin Board will increase interest among the investment community in the Company's efforts to develop alternates to food based feedstocks for biofuels production."
Medical Discoveries, Inc. is now an emerging renewable energy company focused on the production of feedstock used for the production of alternative-energy fuels. The company intends to divest itself of its remaining legacy biopharmaceutical assets, and intends to change its name and ticker symbol to reflect its new focus on the bio-diesel alternative energy market. The company also intends to re-list its shares of common stock on the Over-the-Counter Bulletin Board.
For more info: http://tarof.realpennies.com
Taro Pharmaceutical Industries Ltd. ("Taro," Pink Sheets: TAROF) reported earlier today that it settled a pending lawsuit with Novartis and will be launching Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg ("Oxcarbazepine Tablets") in the United States.
Oxcarbazepine Tablets, marketed by Novartis as Trileptal Tablets, is a prescription pharmaceutical product used in treating seizures. Taro recently settled litigation with Novartis regarding Taro's "Paragraph IV" certification challenging Novartis' patent protection on Trileptal. On November 15, 2007, Taro received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg. The Company did not immediately launch the product at that time, pending settlement of the litigation with Novartis. The Company plans to launch Oxcarbazepine Tablets in the near future. According to industry sources, Trileptal Tablets currently have annual U.S. sales of approximately $700 million.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com
No comments:
Post a Comment